Shoreline Biosciences vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
iPSC-derived allogeneic NK cell and macrophage immunotherapy platform. $183M raised; $300M+ total with partnerships; SMART manufacturing for off-the-shelf cancer cell therapy.
About
Shoreline Biosciences is a clinical-stage biotechnology company harnessing induced pluripotent stem cells (iPSCs) to develop allogeneic, off-the-shelf cellular immunotherapies. The company differentiates iPSCs into natural killer (iNK) cells and macrophages (iMACs) engineered to attack cancer and autoimmune targets. Its proprietary SLEEK knock-in gene-editing technology and industry-leading SMART manufacturing platform are designed to produce scalable, affordable cell therapies without donor matching constraints. Shoreline has raised $183M in equity across two rounds from 18 investors and has secured corporate partnerships valued at over $300M in aggregate support. The pipeline spans both solid tumors and hematologic malignancies, with autoimmune disorder programs announced in late 2024.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.